Clinical Trials Browser

Phase 1 × Withdrawn × Breast Neoplasms × Clear all

NCT06229392 2026-03-11

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Influenza, Human, Triple Negative Breast Neoplasms

NCT05634954 2025-10-23

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT05940844 2025-04-09

Study of OB-002 in Patients With Refractory Metastatic Cancer

Phase 1 Withdrawn

BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06341647 2025-01-24

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Phase 1 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04364672 2024-11-04

Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT05039931 2024-07-18

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms, Lung Neoplasms

NCT06137651 2024-04-01

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT04756505 2023-12-27

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Phase 1 Withdrawn

Breast Neoplasms

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1 Withdrawn

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Phase 1 Withdrawn

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

NCT04054752 2023-11-02

Vaccine Response With NT-I7

Phase 1 Withdrawn

BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colorectal Neoplasms

NCT05600582 2023-10-18

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1 Withdrawn

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05774886 2023-05-18

Implantable Microdevice for TNBC - Pilot Study

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04872608 2023-04-28

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03121989 2023-03-30

LABC

Phase 1 Withdrawn

Breast Neoplasms

NCT03426254 2023-03-29

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms

NCT04252768 2023-03-22

AIPAC-002

Phase 1 Withdrawn

Breast Neoplasms

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT02035085 2022-06-27

CS-1000

Phase 1 Withdrawn

Breast Neoplasms

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03682744 2022-04-06

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Phase 1 Withdrawn

BreastGastrointestinalGynecologic

Breast Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT04142554 2020-11-03

LCCC1820

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast Neoplasms

NCT00706615 2020-07-31

Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT04332549 2020-06-01

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT02619669 2020-03-12

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03721211 2020-03-03

Imaging With [11C]Martinostat in Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03110445 2020-02-07

rVV-740CTA

Phase 1 Withdrawn

Breast Neoplasms

NCT03285607 2018-08-16

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03045393 2018-07-05

IMGN853

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02215083 2017-07-12

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Peripheral Nervous System Diseases

NCT01386502 2017-07-02

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Phase 1 Withdrawn

BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1 Withdrawn

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT02483871 2017-06-05

Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy

Phase 1 Withdrawn

Breast Neoplasms

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT02058667 2016-11-15

Reirradiation With Concurrent Paclitaxel for Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT02627430 2016-07-26

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00006126 2015-11-13

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Phase 1 Withdrawn

BreastDermatologicGenitourinaryThoracic

Testicular Germ Cell Tumor, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Testicular Neoplasms, Small Cell Lung Carcinoma

NCT00704392 2015-08-20

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00635245 2015-03-11

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

Phase 1 Withdrawn

Breast Neoplasms

NCT01320787 2014-10-23

18-F-Fluoroacetate as PET Imaging Agent

Phase 1 Withdrawn

BreastCNSGenitourinary

Brain Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Central Nervous System Neoplasms

NCT01741597 2014-05-30

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

Phase 1 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms

NCT01539876 2014-03-26

TNFactor

Phase 1 Withdrawn

Breast Neoplasms

NCT00074139 2014-03-05

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT01240928 2013-08-20

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT00017537 2013-08-05

Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer

Phase 1 Withdrawn

BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01219907 2013-05-17

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Breast Neoplasms, Male